3.64
+0.25(+7.37%)
Currency In USD
| Previous Close | 3.39 |
| Open | 3.4 |
| Day High | 3.7 |
| Day Low | 3.37 |
| 52-Week High | 3.7 |
| 52-Week Low | 0.65 |
| Volume | 813,646 |
| Average Volume | 690,793 |
| Market Cap | 251.03M |
| PE | -1.96 |
| EPS | -1.86 |
| Moving Average 50 Days | 2.37 |
| Moving Average 200 Days | 1.63 |
| Change | 0.25 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $259.81 as of February 16, 2026 at a share price of $3.64. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $2,821.71 as of February 16, 2026 at a share price of $3.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Announces $25 Million Private Placement
GlobeNewswire Inc.
Feb 13, 2026 12:30 PM GMT
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in pa
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
GlobeNewswire Inc.
Jan 27, 2026 12:00 PM GMT
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide RESEAR